Understanding Your Treatment Options
What is recurrent ovarian cancer?
While it is true that 60% to 80% of ovarian cancer patients respond to their initial treatment, it is very common for ovarian cancer to recur. When this happens, the condition is called recurrent ovarian cancer. DOXIL® is among the treatment options approved by the FDA for recurrent ovarian cancer.
Why your doctor may choose DOXIL®
In clinical trials, DOXIL® was shown to be an effective chemotherapy agent in the treatment of recurrent ovarian cancer. DOXIL® belongs to a group of drugs called anthracyclines, which have been used for many years.
Your doctor may have selected DOXIL® because it is different from other anthracyclines. Find out more about DOXIL® and how it is different.
Recurrent ovarian cancer—a chronic disease?
Many doctors now regard recurrent ovarian cancer as a chronic disease. This means that you may have repeated cycles of illness, treatment, and recovery. While a complete cure may not be possible, in many cases recurrent ovarian cancer can be effectively treated or stabilized for an extended period of time.
How you and your doctor evaluate your treatment options will depend on the type of ovarian cancer you have. The types of ovarian cancer are defined as:
- Platinum-refractory ovarian cancer
Ovarian cancer that progresses during treatment with a platinum-based chemotherapy regimen - Platinum-resistant ovarian cancer
If ovarian cancer recurs within 6 months of completing primary chemotherapy with a platinum-based medication - Platinum-sensitive ovarian cancer
If ovarian cancer recurs more than 6 months after completing primary therapy with a platinum-based medication
